Awarded without open competition
Awarded without open competition. The buyer went directly to one or a few suppliers instead of advertising the contract. Procurement rules allow this only in specific cases, such as extreme urgency, when only one supplier can do the work, or for call-offs from an existing framework.
Key facts
- Buyer
- Gloucestershire Hospitals NHS Foundation Trust · Ministry or any other national or federal authority, including their regional or local subdivisions
- Supplier
- Exact Sciences UK Ltd
- Value
- £229,500
- Procedure
- Award procedure without prior publication of a call for competition
- Sector
- Health & social care · Pathology services (CPV 85111800)
- Region
- South West
- Official notice
- 095328-2026 on Find a Tender
- Timeline
-
- Contract date7 Oct 2026
- Published8 Oct 2026Published 1 day after the contract date
Description
Oncotype DX Breast Recurrence Score is a genomic assay that provides a personalised insight into an individual patient’s breast cancer biology. The Oncotype DX Breast Recurrence Score test addresses the issue overtreatment with chemotherapy, particularly for patients with lymph node-positive breast cancer. In providing a more precise information about tumour biology, it allows many patients to avoid unnecessary chemotherapy. Due to Exact Science being the only provider of this test, the contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023 Direct Award A. The lifetime of the contract is £229,500 from 1st July 2027 until 30th June 2028
About the supplier
Exact Sciences UK Ltd: every public contract they have won, plus their Companies House record (company 07484560).